<DOC>
	<DOCNO>NCT01596426</DOCNO>
	<brief_summary>The purpose study determine dose strategy adolescent age 2 5 year .</brief_summary>
	<brief_title>Safety Pharmacokinetics Sancuso IV Granisetron Patients Aged 2 5 Years</brief_title>
	<detailed_description />
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Granisetron</mesh_term>
	<criteria>1 . 2 5 year age inclusive screening . 2 . Written parental ( appropriate legal representative ) IRB approve informed consent appropriate . 3 . Confirmed malignancy . 4 . Scheduled receive 2 cycles* emetogenic chemotherapy require 5HT3 antagonist treatment . 5 . Scheduled receive one consecutive day 5HT3 antagonist treatment , per cycle , CINV prophylaxis . The cycle chemotherapy must consecutive ( i.e . one follow ) first second cycle line treatment . 1 . Hypersensitivities , allergy contraindication study medication ; intolerance medical tape stick plaster . 2 . Clinical laboratory sign symptom significant cerebral , cardiovascular , respiratory , renal , hepatobiliary , pancreatic infectious disease , Investigator 's judgment may interfere study assessment completion study . 3 . Patients known history predisposition cardiac conduction interval abnormality , include QT Syndrome , know family history long QT Syndrome take medication know prolong QT interval . 4 . Patients schedule routine surgery study duration . 5 . Patients life expectancy &lt; 6 month . 6 . Scarring significant skin disease upper arm . 7 . Administration investigational drug within 30 day precede screen visit , except anticancer treatment . 8 . Any condition associate noncompliance .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>5 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>CINV</keyword>
</DOC>